The recent approval and launch of ALYFTREK for CF further solidifies Vertex's position in its core market. Meanwhile, CASGEVY, the company's gene therapy for sickle cell disease, has begun generating ...

Meanwhile, CASGEVY, the company's gene therapy for sickle cell disease, has begun generating revenue, albeit with a slow ramp-up expected. Over 50 treatment centers have been activated globally ...

When the FDA approved Casgevy as the first therapy using CRISPR gene-editing technology in 2023, sickle cell anemia patients and their caregivers were astonished, hopeful, and concerned. It had been ...

The newest gene therapy treatment, Casgevy, treats sick cell disease and transfusion-dependent beta thalassemia. Its addition means that CHLA provides the most cell and gene therapy treatments for ...

The company recently unveiled several strategic priorities related to the ongoing launch of Casgevy, a one-time gene therapy treatment for blood disorders. Indeed, a breakthrough in this space could ...

Working with CRISPR Therapeutics, Vertex has hit the ground running with Casgevy, its gene therapy for blood disorders. Moreover, its experimental cell therapy for type 1 diabetes, Zimislecel ...

In 2023, Vertex earned approval for Casgevy, a gene-editing treatment for two rare blood-related conditions with very few treatment options. Vertex Pharmaceuticals didn't create Casgevy itself ...

The company is also making progress with Casgevy, its gene therapy treatment. While the launch is in its early stages, with over 50 treatment centers activated globally and more than 50 patients ...

Secondly, McKesson’s dedicated business unit, InspiroGene, partnered with Vertex Pharmaceuticals to expand distribution options for CASGEVY, the first CRISPR-based gene-editing therapy approved ...

Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy Casgevy was approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), in ...